CAMPBELL, CA – (September 24, 2018) – Saama Technologies, Inc., a leading data analytics company, today announced that life sciences and healthcare industry executive, entrepreneur and advisor James M. Karis is joining Saama’s Board of Directors after more than a decade as part of Saama’s Clinical Board of Advisors.
James is a senior executive with over 35 years of experience in the pharmaceutical, healthcare services, technology and medical devices industries. He brings extensive expertise in corporate strategy, operations, clinical research, post launch activities, debt funding, venture and public equity capital, and mergers and acquisitions to his Board of Directors position.
“On behalf of my fellow Board of Directors members, I extend the warmest of welcomes to James. His invaluable contributions as part of Saama’s Clinical Board of Advisors are indicative of the tremendous level of insight and support he will bring to this new position,” said Kenneth Coleman, Chairman of the Board at Saama Technologies. “James’s impressive background in virtually every facet of the life sciences industry makes him an extremely valued and strategic addition to Saama’s Board of Directors.”
Previously, James served as Chief Executive Officer (CEO) of the privately held Mapi Group, a company focused on conducting late phase studies as well as providing regulatory and reimbursement support to the pharmaceutical and device industries. Prior experience includes tenures as CEO of oncology informatics company CollabRx, Inc., President and CEO of biology modeling and predictive analytics company Entelos, Inc., and President and COO of contract research organization PAREXEL International.
James is an experienced Board member for public and private companies, currently serving as non-executive director of Shield Therapeutics, and formerly occupying Board positions at DataTrak, CollabRx, Marina Biotech, Inc., Schulman IRB Holding Company, and Entelos, Inc.
Saama Technologies is the advanced clinical data and analytics company, unleashing wisdom from data to deliver better business outcomes for the life sciences industry. Saama’s unified, AI-driven clinical data analytics platform seamlessly integrates, curates, and animates unlimited sources of structured, unstructured, and real-world data to deliver actionable insights across all therapeutic areas. The award-winning platform gives unprecedented real-time visibility into clinical data, enabling sponsors to file New Drug Applications (NDAs) more efficiently to bring drugs to market faster and at lower costs. For more information, visit http://www.saama.com.